{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(2)"],"submitter":["Cho WC"],"pubmed_abstract":["Nasopharyngeal carcinoma (NPC) initially responds well to platinum-based therapy but often develops resistance. Combining therapies may offer a viable approach to address this resistance. Heat shock protein 90 (Hsp90) has shown promising anticancer activity in various cancer types. This study aimed to investigate the efficacy of an Hsp90 inhibitor, luminespib (AUY922), and evaluate the synergistic effect of combining AUY922 with cisplatin on two cisplatin-resistant human NPC cell lines. The response of cisplatin-resistant NPC cells to AUY922 and/or cisplatin was assessed through proliferation assay, cell cycle analysis, Annexin V apoptosis detection, Western blot analysis, <i>in vivo</i> investigation, and histological analysis. Our results indicated that AUY922/cisplatin combination signi"],"journal":["American journal of cancer research"],"pagination":["533-545"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11897633"],"repository":["biostudies-literature"],"pubmed_title":["Potential benefits of combined treatment with Hsp90 inhibitor AUY922 and cisplatin for overcoming drug resistance in nasopharyngeal carcinoma."],"pmcid":["PMC11897633"],"pubmed_authors":["Cho WC","Wong CF"],"additional_accession":[]},"is_claimable":false,"name":"Potential benefits of combined treatment with Hsp90 inhibitor AUY922 and cisplatin for overcoming drug resistance in nasopharyngeal carcinoma.","description":"Nasopharyngeal carcinoma (NPC) initially responds well to platinum-based therapy but often develops resistance. Combining therapies may offer a viable approach to address this resistance. Heat shock protein 90 (Hsp90) has shown promising anticancer activity in various cancer types. This study aimed to investigate the efficacy of an Hsp90 inhibitor, luminespib (AUY922), and evaluate the synergistic effect of combining AUY922 with cisplatin on two cisplatin-resistant human NPC cell lines. The response of cisplatin-resistant NPC cells to AUY922 and/or cisplatin was assessed through proliferation assay, cell cycle analysis, Annexin V apoptosis detection, Western blot analysis, <i>in vivo</i> investigation, and histological analysis. Our results indicated that AUY922/cisplatin combination signi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2025-04-04T09:06:45.93Z","creation":"2025-04-04T09:06:45.93Z"},"accession":"S-EPMC11897633","cross_references":{"pubmed":["40084353"],"doi":["10.62347/OSGO7209","10.62347/osgo7209"]}}